Gene · 4921
Papers2,653
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
821 to 840 of 2,653
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Next Generation Sequencing Technology in Lung Cancer Diagnosis. | Biology (Basel) | 2021 | 34571741 | PubTator, text mining | PubMed |
| Metastatic Castration-Resistant Prostate Cancer Remains Dependent on Oncogenic Drivers Found in Primary Tumors. | JCO Precis Oncol | 2021 | 34568716 | PubTator, text mining | PubMed |
| Regenerative Medicine for the Treatment of Ischemic Heart Disease; Status and Future Perspectives. | Front Cell Dev Biol | 2021 | 34568321 | PubTator, text mining | PubMed |
| Systems-Level Proteomics Evaluation of Microglia Response to Tumor-Supportive Anti-Inflammatory Cytokines. | Front Immunol | 2021 | 34566949 | PubTator, text mining | PubMed |
| Growth factor signaling predicts therapy resistance mechanisms and defines neuroblastoma subtypes. | Oncogene | 2021 | 34556815 | PubTator, text mining | PubMed |
| Expression and subcellular localization of Discoidin Domain Receptor 1 (DDR1) define prostate cancer aggressiveness. | Cancer Cell Int | 2021 | 34548097 | PubTator, text mining | PubMed |
| TP53 and CDKN2A mutations in patients with early-stage lung squamous cell carcinoma: an analysis of the correlations and prognostic outcomes. | Ann Transl Med | 2021 | 34532467 | PubTator, text mining | PubMed |
| Co-mutations of epidermal growth factor receptor and BRAF in Chinese non-small cell lung cancer patients. | Ann Transl Med | 2021 | 34532458 | PubTator, text mining | PubMed |
| A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. | Cancer Med | 2021 | 34528763 | PubTator, text mining | PubMed |
| Genomic alteration profiles of lung cancer and their relationship to clinical features and prognosis value using individualized genetic testing. | J Thorac Dis | 2021 | 34527339 | PubTator, text mining | PubMed |
| Current Challenges in Targeting Tumor Desmoplasia to Improve the Efficacy of Immunotherapy. | Curr Cancer Drug Targets | 2021 | 34525931 | PubTator, text mining | PubMed |
| In Vivo Efficacy of Imatinib Mesylate, a Tyrosine Kinase Inhibitor, in the Treatment of Chemically Induced Dry Eye in Animal Models. | Transl Vis Sci Technol | 2021 | 34520512 | PubTator, text mining | PubMed |
| A Case of Adult Pancreatoblastoma With Novel APC Mutation and Genetic Heterogeneity. | Front Oncol | 2021 | 34513702 | PubTator, text mining | PubMed |
| Testing for EGFR Mutations and ALK Rearrangements in Advanced Non-Small-Cell Lung Cancer: Considerations for Countries in Emerging Markets. | Onco Targets Ther | 2021 | 34511936 | PubTator, text mining | PubMed |
| Development of a Selective Dual Discoidin Domain Receptor (DDR)/p38 Kinase Chemical Probe. | J Med Chem | 2021 | 34506142 | PubTator, text mining | PubMed |
| A Multi-Omics Approach Using a Mouse Model of Cardiac Malformations for Prioritization of Human Congenital Heart Disease Contributing Genes. | Front Cardiovasc Med | 2021 | 34504875 | PubTator, text mining | PubMed |
| Comprehensively Exploring the Mutational Landscape and Patterns of Genomic Evolution in Hypermutated Cancers. | Cancers (Basel) | 2021 | 34503126 | PubTator, text mining | PubMed |
Fibroblast Growth Factor Inhibitors for Treating Locally Advanced/Metastatic Bladder Urothelial Carcinomas via Dual Targeting of Tumor-Specific Oncogenic Signaling and the Tumor Immune Microenvironment. | Int J Mol Sci | 2021 | 34502435 | PubTator, text mining | PubMed |
| Discoidin Domain Receptor 2 Regulates AT1R Expression in Angiotensin II-Stimulated Cardiac Fibroblasts via Fibronectin-Dependent Integrin-β1 Signaling. | Int J Mol Sci | 2021 | 34502259 | PubTator, text mining | PubMed |
| Merestinib monotherapy or in combination for japanese patients with advanced and/or metastatic cancer: A phase 1 study. | Cancer Med | 2021 | 34499416 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4921/papers?page=42